Pre- and post-translational regulation of osteopontin in cancer

  • Pieter H. Anborgh
  • Jennifer C. Mutrie
  • Alan B. Tuck
  • Ann F. Chambers
Review

Abstract

Osteopontin (OPN) is a matricellular protein that binds to a number of cell surface receptors including integrins and CD44. It is expressed in many tissues and secreted into body fluids including blood, milk and urine. OPN plays important physiological roles in bone remodeling, immune response and inflammation. It is also a tumour-associated protein, and elevated OPN levels are associated with tumour formation, progression and metastasis. Research has revealed a promising role for OPN as a cancer biomarker. OPN is subject to alternative splicing, as well as post-translational modifications such as phosphorylation, glycosylation and proteolytic cleavage. Functional differences have been revealed for different isoforms and post-translational modifications. The pattern of isoform expression and post-translational modification is cell-type specific and may influence the potential role of OPN in malignancy and as a cancer biomarker.

Keywords

Osteopontin Cancer Metastasis Matricellular protein Post-translational modification Alternative splicing 

Abbreviations

ECM

Extracellular matrix

ELISA

Enzyme-linked immunosorbent assay

HCC

Hepatocellular carcinoma

HNSCC

Head and neck squamous cell carcinoma

MM

Malignant mesothelioma

MMP

Matrix metalloproteinase

mRNA

Messenger ribonucleic acid

NSCLC

Non-small cell lung cancer

OPN

Osteopontin

PDA

Pancreatic ductal adenocarcinoma

Q

Glutamine

qRT-PCR

Quantitative real time polymerase chain reaction

RT-PCR

Real time polymerase chain reaction

RGD

Arginine-Glycine-Aspartic acid

siRNA

Small interfering ribonucleic acid

shRNA

Short hairpin ribonucleic acid

SVVYGLR

Serine-Valine-Valine-Tyrosine-Glycine-Leucine-Arginine

TG2

Tissue transglutaminase

uPA

Urokinase plasminogen activator

Notes

Acknowledgements

This work is supported by an award from the Lloyd Carr-Harris Foundation. JCM is supported by a Canadian Graduate Award from the Canadian Institutes of Health Research and a Studentship from the Translational Breast Cancer Research Unit at the London Regional Cancer Program. AFC is a Canada Research Chair in Oncology, supported by the Canada Research Chairs Program.

References

  1. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276(30):28261–28267PubMedCrossRefGoogle Scholar
  2. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94(7):513–521PubMedGoogle Scholar
  3. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, Al-Katib W, Stitt LW, Uede T, Chambers AF, Tuck AB (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169(1):233–246PubMedCrossRefGoogle Scholar
  4. Al-Shami R, Sorensen ES, Ek-Rylander B, Andersson G, Carson DD, Farach-Carson MC (2005) Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem 94(6):1218–1233PubMedCrossRefGoogle Scholar
  5. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF (2009) New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 55(5):895–903PubMedCrossRefGoogle Scholar
  6. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2010) Role of the metastasis-promoting protein osteopontin in the tumor microenvironment. J Cell Mol Med 14(8):2037–2044PubMedCrossRefGoogle Scholar
  7. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Wurl P, Taubert H, Vordermark D (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10:132PubMedCrossRefGoogle Scholar
  8. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T (2007) Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 14(3):373–381PubMedCrossRefGoogle Scholar
  9. Blasberg JD, Goparaju CM, Pass HI, Donington JS (2009) Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 139(6):1587–1593PubMedCrossRefGoogle Scholar
  10. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS (2010) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28(6):936–941PubMedCrossRefGoogle Scholar
  11. Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF (2005) Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther 4(12):1336–1341PubMedCrossRefGoogle Scholar
  12. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343PubMedCrossRefGoogle Scholar
  13. Brinkman BM (2004) Splice variants as cancer biomarkers. Clin Biochem 37(7):584–594PubMedCrossRefGoogle Scholar
  14. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145(3):610–623PubMedGoogle Scholar
  15. Cao Z, Dai J, Fan K, Wang H, Ji G, Li B, Zhang D, Hou S, Qian W, Zhao J, Wang H, Guo Y (2008) A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol 45(14):3683–3692PubMedCrossRefGoogle Scholar
  16. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P (2010) Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 12(3):204PubMedCrossRefGoogle Scholar
  17. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW (2009) Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35(6):1409–1416PubMedGoogle Scholar
  18. Chakraborty G, Jain S, Patil TV, Kundu GC (2008) Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 12(6A):2305–2318PubMedCrossRefGoogle Scholar
  19. Chambers AF, Wilson SM, Kerkvliet N, O’Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancer. Lung Cancer 15(3):311–323PubMedCrossRefGoogle Scholar
  20. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ (2008) Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 56(1):57–66PubMedCrossRefGoogle Scholar
  21. Chen RX, Xia YH, Xue TC, Zhang H, Ye SL (2011) Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25(3):803-808Google Scholar
  22. Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC (2009) Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 45(9):798–802PubMedCrossRefGoogle Scholar
  23. Cho HJ, Cho HJ, Kim HS (2009) Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11(3):206–213PubMedCrossRefGoogle Scholar
  24. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: Identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390(Pt 1):285–292PubMedGoogle Scholar
  25. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sorensen ES (2007) Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282(27):19463–19472PubMedCrossRefGoogle Scholar
  26. Christensen B, Petersen TE, Sorensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411(1):53–61PubMedCrossRefGoogle Scholar
  27. Collighan RJ, Griffin M (2009) Transglutaminase 2 cross-linking of matrix proteins: Biological significance and medical applications. Amino Acids 36(4):659–670PubMedCrossRefGoogle Scholar
  28. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43(4):225–236PubMedCrossRefGoogle Scholar
  29. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10(1 Pt 1):184–190PubMedCrossRefGoogle Scholar
  30. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 5(3):e9633PubMedCrossRefGoogle Scholar
  31. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K (2007) Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57(3):302–310PubMedCrossRefGoogle Scholar
  32. Dai J, Cao Z, Kang Y, Fan K, Ji G, Yang H, Wang H, Gao J, Wang H, Guo Y (2009) A functional motif QLYxxYP is essential for osteopontin induced T lymphocyte activation and migration. Biochem Biophys Res Commun 380(3):715–720PubMedCrossRefGoogle Scholar
  33. Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, Hou S, Zhao L, Gao J, Cao Z, Zhao J, Wang H, Guo Y (2010) A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 59(3):355–366PubMedCrossRefGoogle Scholar
  34. Dean RA, Overall CM (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6(4):611–623PubMedCrossRefGoogle Scholar
  35. Ecarot-Charrier B, Bouchard F, Delloye C (1989) Bone sialoprotein II synthesized by cultured osteoblasts contains tyrosine sulfate. J Biol Chem 264(33):20049–20053PubMedGoogle Scholar
  36. Ek-Rylander B, Andersson G (2010) Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 316(3):443–451PubMedCrossRefGoogle Scholar
  37. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G (1994) Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. modulation of osteoclast adhesion in vitro. J Biol Chem 269(21):14853–14856PubMedGoogle Scholar
  38. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118(9):2255–2261PubMedCrossRefGoogle Scholar
  39. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621–632PubMedCrossRefGoogle Scholar
  40. Gaumann A, Petrow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ, Kriegsmann J (2001) Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 439(5):668–674PubMedGoogle Scholar
  41. Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19(7):615–622PubMedCrossRefGoogle Scholar
  42. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS (2010) Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5(10):1516–1523PubMedCrossRefGoogle Scholar
  43. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, Vinson AR, Be CL, Li S, Sorensen ES, Tam PP, Denhardt DT, Sheppard D, Choong PF, Nilsson SK (2009) Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114(1):49–59PubMedCrossRefGoogle Scholar
  44. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRefGoogle Scholar
  45. He B, Mirza M, Weber GF (2006) An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25(15):2192–2202PubMedCrossRefGoogle Scholar
  46. Higashikawa F, Eboshida A, Yokosaki Y (2007) Enhanced biological activity of polymeric osteopontin. FEBS Lett 581(14):2697–2701PubMedCrossRefGoogle Scholar
  47. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 303(Pt 1):255–262PubMedGoogle Scholar
  48. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95(3):506–512PubMedCrossRefGoogle Scholar
  49. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, Imamoto H, Okuno K, Ito H, Shiozaki H, Ohyanagi H (2009) Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13(9):1577–1582PubMedCrossRefGoogle Scholar
  50. Irby RB, McCarthy SM, Yeatman TJ (2004) Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21(6):515–523PubMedCrossRefGoogle Scholar
  51. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI (2009) Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382(3):514–518PubMedCrossRefGoogle Scholar
  52. Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM (2009) Sialyl-tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 100(11):1746–1754PubMedCrossRefGoogle Scholar
  53. Kaartinen MT, El-Maadawy S, Rasanen NH, McKee MD (2002) Tissue transglutaminase and its substrates in bone. J Bone Miner Res 17(12):2161–2173PubMedCrossRefGoogle Scholar
  54. Kaartinen MT, Murshed M, Karsenty G, McKee MD (2007) Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of matrix gla protein-deficient mice. J Histochem Cytochem 55(4):375–386PubMedCrossRefGoogle Scholar
  55. Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102(4):912–924PubMedCrossRefGoogle Scholar
  56. Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G (2005) Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44(18):6990–7003PubMedCrossRefGoogle Scholar
  57. Kiefer MC, Bauer DM, Barr PJ (1989) The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res 17(8):3306PubMedCrossRefGoogle Scholar
  58. Kunii Y, Niwa S, Hagiwara Y, Maeda M, Seitoh T, Suzuki T (2009) The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems. Med Mol Morphol 42(3):155–161PubMedCrossRefGoogle Scholar
  59. Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90(6):986–992PubMedGoogle Scholar
  60. Lasa M, Chang PL, Prince CW, Pinna LA (1997) Phosphorylation of osteopontin by golgi apparatus casein kinase. Biochem Biophys Res Commun 240(3):602–605PubMedCrossRefGoogle Scholar
  61. Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 14(1):74–81PubMedCrossRefGoogle Scholar
  62. Lin F, Li Y, Cao J, Fan S, Wen J, Zhu G, Du H, Liang Y (2010) Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol RepGoogle Scholar
  63. Liu H, Chen A, Guo F, Yuan L (2010) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295(1):27–37PubMedCrossRefGoogle Scholar
  64. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26(17):2459–2470PubMedCrossRefGoogle Scholar
  65. Masuda K, Takahashi N, Tsukamoto Y, Honma H, Kohri K (2000) N-glycan structures of an osteopontin from human bone. Biochem Biophys Res Commun 268(3):814–817PubMedCrossRefGoogle Scholar
  66. Mehta K, Fok J, Miller FR, Koul D, Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10(23):8068–8076PubMedCrossRefGoogle Scholar
  67. Mi Z, Oliver T, Guo H, Gao C, Kuo PC (2007) Thrombin-cleaved COOH(−) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 67(9):4088–4097PubMedCrossRefGoogle Scholar
  68. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC (2009) RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 17(1):153–161PubMedCrossRefGoogle Scholar
  69. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF (2008) Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122(4):889–897PubMedCrossRefGoogle Scholar
  70. Nagata T, Todescan R, Goldberg HA, Zhang Q, Sodek J (1989) Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Commun 165(1):234–240PubMedCrossRefGoogle Scholar
  71. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15):1564–1573PubMedCrossRefGoogle Scholar
  72. Patani N, Jouhra F, Jiang W, Mokbel K (2008) Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 28(6B):4105–4110PubMedGoogle Scholar
  73. Prince CW, Dickie D, Krumdieck CL (1991) Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem Biophys Res Commun 177(3):1205–1210PubMedCrossRefGoogle Scholar
  74. Rangaswami H, Bulbule A, Kundu GC (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 279(37):38921–38935PubMedCrossRefGoogle Scholar
  75. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79–87PubMedCrossRefGoogle Scholar
  76. Reinholt FP, Hultenby K, Oldberg A, Heinegard D (1990) Osteopontin–a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 87(12):4473–4475PubMedCrossRefGoogle Scholar
  77. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90(10):1877–1881PubMedCrossRefGoogle Scholar
  78. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16(6):1087–1097PubMedCrossRefGoogle Scholar
  79. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva RS, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–3427PubMedGoogle Scholar
  80. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123(2):263–270PubMedCrossRefGoogle Scholar
  81. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y (1995) Expression of osteopontin in human glioma. its correlation with the malignancy. Lab Invest 72(1):55–63PubMedGoogle Scholar
  82. Salih E, Ashkar S, Gerstenfeld LC, Glimcher MJ (1997) Identification of the phosphorylated sites of metabolically 32P-labeled osteopontin from cultured chicken osteoblasts. J Biol Chem 272(21):13966–13973PubMedCrossRefGoogle Scholar
  83. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, Chambers AF, Allan AL (2008) The thrombin inhibitor argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 112(2):243–254PubMedCrossRefGoogle Scholar
  84. Senger DR, Perruzzi CA, Papadopoulos A (1989) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9(5):1291–1299PubMedGoogle Scholar
  85. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L (1994) Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5(5):565–574PubMedGoogle Scholar
  86. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB (1997) Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36(19):5729–5738PubMedCrossRefGoogle Scholar
  87. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23(2):123–133PubMedCrossRefGoogle Scholar
  88. Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3(4):605–611PubMedGoogle Scholar
  89. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, Giachelli CM (1996) Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 271(45):28485–28491PubMedCrossRefGoogle Scholar
  90. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11(3):279–303PubMedCrossRefGoogle Scholar
  91. Sorensen ES, Rasmussen LK, Moller L, Jensen PH, Hojrup P, Petersen TE (1994) Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem J 304(Pt 1):13–16PubMedGoogle Scholar
  92. Sorensen ES, Hojrup P, Petersen TE (1995) Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4(10):2040–2049PubMedCrossRefGoogle Scholar
  93. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K (2010) Identification of potential serum biomarkers of glioblastoma: Serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19(6):1409–1422PubMedCrossRefGoogle Scholar
  94. Stone MJ, Chuang S, Hou X, Shoham M, Zhu JZ (2009). Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. New Biotechnol 25(5):299–317.CrossRefGoogle Scholar
  95. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA (2009) Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146(2):232–240PubMedCrossRefGoogle Scholar
  96. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A (2002) Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441(4):345–349PubMedCrossRefGoogle Scholar
  97. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26(44):6361–6371PubMedCrossRefGoogle Scholar
  98. Takahashi K, Takahashi F, Tanabe KK, Takahashi H, Fukuchi Y (1998) The carboxyl-terminal fragment of osteopontin suppresses arginine-glycine-asparatic acid-dependent cell adhesion. Biochem Mol Biol Int 46(6):1081–1092PubMedGoogle Scholar
  99. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A, Syrigos KN (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29(5):1651–1657PubMedGoogle Scholar
  100. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6(4):419–429PubMedCrossRefGoogle Scholar
  101. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121(6):578–584PubMedGoogle Scholar
  102. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79(5):502–508PubMedCrossRefGoogle Scholar
  103. Tuck AB, Arsenault DM, O’Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18(29):4237–4246PubMedCrossRefGoogle Scholar
  104. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (met). J Cell Biochem 78(3):465–475PubMedCrossRefGoogle Scholar
  105. Tuck AB, Hota C, Wilson SM, Chambers AF (2003) Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22(8):1198–1205PubMedCrossRefGoogle Scholar
  106. Tuck AB, Chambers AF, Allan AL (2007) Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102(4):859–868PubMedCrossRefGoogle Scholar
  107. Venables JP, Koh CS, Froehlich U, Lapointe E, Couture S, Inkel L, Bramard A, Paquet ER, Watier V, Durand M, Lucier JF, Gervais-Bird J, Tremblay K, Prinos P, Klinck R, Elela SA, Chabot B (2008) Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol Cell Biol 28(19):6033–6043PubMedCrossRefGoogle Scholar
  108. Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 121(2):228–241PubMedCrossRefGoogle Scholar
  109. Wai PY, Kuo PC (2008) Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev 27(1):103–118PubMedCrossRefGoogle Scholar
  110. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552(2):61–85PubMedGoogle Scholar
  111. Weber GF, Lett GS, Haubein NC (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103(6):861–869PubMedCrossRefGoogle Scholar
  112. Xuan JW, Hota C, Chambers AF (1994) Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 54(2):247–255PubMedCrossRefGoogle Scholar
  113. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y (2010) Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 12(8):765–775PubMedCrossRefGoogle Scholar
  114. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9(4):416–423PubMedCrossRefGoogle Scholar
  115. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274(51):36328–36334PubMedCrossRefGoogle Scholar
  116. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW (1990) cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7(4):491–502PubMedCrossRefGoogle Scholar
  117. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y (2001) Differential osteopontin expression in lung cancer. Cancer Lett 171(2):215–222PubMedCrossRefGoogle Scholar
  118. Zhang H, Hunter GK, Goldberg HA, Lajoie GA, Yeung KK (2007) An integrated procedure of selective injection, sample stacking and fractionation of phosphopeptides for MALDI MS analysis. Anal Chim Acta 581(2):268–280PubMedCrossRefGoogle Scholar
  119. Zhang X, Tsukamoto T, Mizoshita T, Ban H, Suzuki H, Toyoda T, Tatematsu M (2009) Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer. Oncol Rep 21(3):609–613PubMedGoogle Scholar
  120. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W (2011) Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin OncolGoogle Scholar

Copyright information

© The International CCN Society 2011

Authors and Affiliations

  • Pieter H. Anborgh
    • 1
  • Jennifer C. Mutrie
    • 1
    • 2
  • Alan B. Tuck
    • 1
    • 2
    • 3
    • 4
  • Ann F. Chambers
    • 1
    • 2
    • 4
  1. 1.London Regional Cancer ProgramLondonCanada
  2. 2.Department of PathologyUniversity of Western OntarioLondonCanada
  3. 3.London Health Sciences CentreLondonCanada
  4. 4.Department of OncologyUniversity of Western OntarioLondonCanada

Personalised recommendations